1. Biotechnology

Vedanta's live bacteria cocktail fails to reduce ulcerative colitis severity in phase 2 trial

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease have been dashed. The Massachusetts-based microbiome outfit’s mixture of 16 bacterial strains failed to reduce disease severity in the colons of patients with ulcerative colitis, Vedanta said Wednesday.

Comments to: Vedanta's live bacteria cocktail fails to reduce ulcerative colitis severity in phase 2 trial

Login

Welcome to Life Science News!

"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.